The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm : conceptual framework and therapeutic potential
In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Ele...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Journal Article |
| Language: | English |
| Published: |
2019
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10356/87826 http://hdl.handle.net/10220/49307 |
| _version_ | 1824453599074189312 |
|---|---|
| author | Fruchart, Jean-Charles Santos, Raul D. Aguilar-Salinas, Carlos Aikawa, Masanori Kodama, Tatsuhiko Rasadi, Khalid Al Amarenco, Pierre Barter, Philip J. Ceska, Richard Corsini, Alberto Després, Jean-Pierre Duriez, Patrick Eckel, Robert H. Ezhov, Marat V. Farnier, Michel Ginsberg, Henry N. Hermans, Michel P. Ishibashi, Shun Karpe, Fredrik Koenig, Wolfgang Krempf, Michel Lim, Soo Lorenzatti, Alberto J. McPherson, Ruth Nuñez-Cortes, Jesus Millan Nordestgaard, Børge G. Ogawa, Hisao Packard, Chris J. Plutzky, Jorge Ponte-Negretti, Carlos I. Pradhan, Aruna Ray, Kausik K. Reiner, Željko Ridker, Paul M. Ruscica, Massimiliano Sadikot, Shaukat Shimano, Hitoshi Sritara, Piyamitr Stock, Jane K. Su, Ta-Chen Susekov, Andrey V. Tartar, André Taskinen, Marja-Riitta Tenenbaum, Alexander Tokgözoğlu, Lale S. Tomlinson, Brian Tybjærg-Hansen, Anne Valensi, Paul Vrablík, Michal Wahli, Walter Watts, Gerald F. Yamashita, Shizuya Yokote, Koutaro Zambon, Alberto Libby, Peter |
| author2 | Lee Kong Chian School of Medicine (LKCMedicine) |
| author_facet | Lee Kong Chian School of Medicine (LKCMedicine) Fruchart, Jean-Charles Santos, Raul D. Aguilar-Salinas, Carlos Aikawa, Masanori Kodama, Tatsuhiko Rasadi, Khalid Al Amarenco, Pierre Barter, Philip J. Ceska, Richard Corsini, Alberto Després, Jean-Pierre Duriez, Patrick Eckel, Robert H. Ezhov, Marat V. Farnier, Michel Ginsberg, Henry N. Hermans, Michel P. Ishibashi, Shun Karpe, Fredrik Koenig, Wolfgang Krempf, Michel Lim, Soo Lorenzatti, Alberto J. McPherson, Ruth Nuñez-Cortes, Jesus Millan Nordestgaard, Børge G. Ogawa, Hisao Packard, Chris J. Plutzky, Jorge Ponte-Negretti, Carlos I. Pradhan, Aruna Ray, Kausik K. Reiner, Željko Ridker, Paul M. Ruscica, Massimiliano Sadikot, Shaukat Shimano, Hitoshi Sritara, Piyamitr Stock, Jane K. Su, Ta-Chen Susekov, Andrey V. Tartar, André Taskinen, Marja-Riitta Tenenbaum, Alexander Tokgözoğlu, Lale S. Tomlinson, Brian Tybjærg-Hansen, Anne Valensi, Paul Vrablík, Michal Wahli, Walter Watts, Gerald F. Yamashita, Shizuya Yokote, Koutaro Zambon, Alberto Libby, Peter |
| author_sort | Fruchart, Jean-Charles |
| collection | NTU |
| description | In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk. |
| first_indexed | 2025-02-19T03:08:58Z |
| format | Journal Article |
| id | ntu-10356/87826 |
| institution | Nanyang Technological University |
| language | English |
| last_indexed | 2025-02-19T03:08:58Z |
| publishDate | 2019 |
| record_format | dspace |
| spelling | ntu-10356/878262020-11-01T05:30:07Z The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm : conceptual framework and therapeutic potential Fruchart, Jean-Charles Santos, Raul D. Aguilar-Salinas, Carlos Aikawa, Masanori Kodama, Tatsuhiko Rasadi, Khalid Al Amarenco, Pierre Barter, Philip J. Ceska, Richard Corsini, Alberto Després, Jean-Pierre Duriez, Patrick Eckel, Robert H. Ezhov, Marat V. Farnier, Michel Ginsberg, Henry N. Hermans, Michel P. Ishibashi, Shun Karpe, Fredrik Koenig, Wolfgang Krempf, Michel Lim, Soo Lorenzatti, Alberto J. McPherson, Ruth Nuñez-Cortes, Jesus Millan Nordestgaard, Børge G. Ogawa, Hisao Packard, Chris J. Plutzky, Jorge Ponte-Negretti, Carlos I. Pradhan, Aruna Ray, Kausik K. Reiner, Željko Ridker, Paul M. Ruscica, Massimiliano Sadikot, Shaukat Shimano, Hitoshi Sritara, Piyamitr Stock, Jane K. Su, Ta-Chen Susekov, Andrey V. Tartar, André Taskinen, Marja-Riitta Tenenbaum, Alexander Tokgözoğlu, Lale S. Tomlinson, Brian Tybjærg-Hansen, Anne Valensi, Paul Vrablík, Michal Wahli, Walter Watts, Gerald F. Yamashita, Shizuya Yokote, Koutaro Zambon, Alberto Libby, Peter Lee Kong Chian School of Medicine (LKCMedicine) Residual Cardiovascular Risk Visceral Obesity Science::Medicine In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk. Published version 2019-07-11T09:17:34Z 2019-12-06T16:50:16Z 2019-07-11T09:17:34Z 2019-12-06T16:50:16Z 2019 Journal Article Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Rasadi, K. A., Amarenco, P., . . . Libby, P. (2019). The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm : conceptual framework and therapeutic potential. Cardiovascular Diabetology, 18(1), 71-. doi:10.1186/s12933-019-0864-7 https://hdl.handle.net/10356/87826 http://hdl.handle.net/10220/49307 10.1186/s12933-019-0864-7 en Cardiovascular Diabetology © 2019 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. 20 p. application/pdf |
| spellingShingle | Residual Cardiovascular Risk Visceral Obesity Science::Medicine Fruchart, Jean-Charles Santos, Raul D. Aguilar-Salinas, Carlos Aikawa, Masanori Kodama, Tatsuhiko Rasadi, Khalid Al Amarenco, Pierre Barter, Philip J. Ceska, Richard Corsini, Alberto Després, Jean-Pierre Duriez, Patrick Eckel, Robert H. Ezhov, Marat V. Farnier, Michel Ginsberg, Henry N. Hermans, Michel P. Ishibashi, Shun Karpe, Fredrik Koenig, Wolfgang Krempf, Michel Lim, Soo Lorenzatti, Alberto J. McPherson, Ruth Nuñez-Cortes, Jesus Millan Nordestgaard, Børge G. Ogawa, Hisao Packard, Chris J. Plutzky, Jorge Ponte-Negretti, Carlos I. Pradhan, Aruna Ray, Kausik K. Reiner, Željko Ridker, Paul M. Ruscica, Massimiliano Sadikot, Shaukat Shimano, Hitoshi Sritara, Piyamitr Stock, Jane K. Su, Ta-Chen Susekov, Andrey V. Tartar, André Taskinen, Marja-Riitta Tenenbaum, Alexander Tokgözoğlu, Lale S. Tomlinson, Brian Tybjærg-Hansen, Anne Valensi, Paul Vrablík, Michal Wahli, Walter Watts, Gerald F. Yamashita, Shizuya Yokote, Koutaro Zambon, Alberto Libby, Peter The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm : conceptual framework and therapeutic potential |
| title | The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm : conceptual framework and therapeutic potential |
| title_full | The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm : conceptual framework and therapeutic potential |
| title_fullStr | The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm : conceptual framework and therapeutic potential |
| title_full_unstemmed | The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm : conceptual framework and therapeutic potential |
| title_short | The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm : conceptual framework and therapeutic potential |
| title_sort | selective peroxisome proliferator activated receptor alpha modulator spparmα paradigm conceptual framework and therapeutic potential |
| topic | Residual Cardiovascular Risk Visceral Obesity Science::Medicine |
| url | https://hdl.handle.net/10356/87826 http://hdl.handle.net/10220/49307 |
| work_keys_str_mv | AT fruchartjeancharles theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT santosrauld theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT aguilarsalinascarlos theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT aikawamasanori theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT kodamatatsuhiko theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT rasadikhalidal theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT amarencopierre theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT barterphilipj theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT ceskarichard theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT corsinialberto theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT despresjeanpierre theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT duriezpatrick theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT eckelroberth theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT ezhovmaratv theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT farniermichel theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT ginsberghenryn theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT hermansmichelp theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT ishibashishun theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT karpefredrik theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT koenigwolfgang theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT krempfmichel theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT limsoo theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT lorenzattialbertoj theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT mcphersonruth theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT nunezcortesjesusmillan theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT nordestgaardbørgeg theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT ogawahisao theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT packardchrisj theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT plutzkyjorge theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT pontenegretticarlosi theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT pradhanaruna theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT raykausikk theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT reinerzeljko theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT ridkerpaulm theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT ruscicamassimiliano theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT sadikotshaukat theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT shimanohitoshi theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT sritarapiyamitr theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT stockjanek theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT sutachen theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT susekovandreyv theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT tartarandre theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT taskinenmarjariitta theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT tenenbaumalexander theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT tokgozoglulales theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT tomlinsonbrian theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT tybjærghansenanne theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT valensipaul theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT vrablikmichal theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT wahliwalter theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT wattsgeraldf theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT yamashitashizuya theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT yokotekoutaro theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT zambonalberto theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT libbypeter theselectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT fruchartjeancharles selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT santosrauld selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT aguilarsalinascarlos selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT aikawamasanori selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT kodamatatsuhiko selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT rasadikhalidal selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT amarencopierre selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT barterphilipj selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT ceskarichard selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT corsinialberto selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT despresjeanpierre selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT duriezpatrick selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT eckelroberth selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT ezhovmaratv selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT farniermichel selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT ginsberghenryn selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT hermansmichelp selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT ishibashishun selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT karpefredrik selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT koenigwolfgang selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT krempfmichel selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT limsoo selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT lorenzattialbertoj selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT mcphersonruth selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT nunezcortesjesusmillan selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT nordestgaardbørgeg selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT ogawahisao selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT packardchrisj selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT plutzkyjorge selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT pontenegretticarlosi selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT pradhanaruna selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT raykausikk selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT reinerzeljko selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT ridkerpaulm selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT ruscicamassimiliano selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT sadikotshaukat selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT shimanohitoshi selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT sritarapiyamitr selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT stockjanek selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT sutachen selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT susekovandreyv selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT tartarandre selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT taskinenmarjariitta selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT tenenbaumalexander selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT tokgozoglulales selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT tomlinsonbrian selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT tybjærghansenanne selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT valensipaul selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT vrablikmichal selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT wahliwalter selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT wattsgeraldf selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT yamashitashizuya selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT yokotekoutaro selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT zambonalberto selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential AT libbypeter selectiveperoxisomeproliferatoractivatedreceptoralphamodulatorspparmaparadigmconceptualframeworkandtherapeuticpotential |